Emmis Acquisition (EMIS) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Emmis Acquisition (EMIS) has outperformed Yarrow Bioscience (YARW) over the past year, gaining 3.3% versus a loss of 3.1%. Yarrow Bioscience is the larger company by market cap ($170.4 million vs $162.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | YARW |
|---|---|---|
| Share price | $10.28 | $18.31 |
| Market cap | $162.18M | $170.36M |
| 1-day change | +0.10% | -8.45% |
| YTD return | +3.32% | -36.86% |
| 1-year return | +3.32% | -3.12% |
| 5-year return | — | -98.22% |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $570.00K |
| Revenue growth (YoY) | — | +13.77% |
| Net income (latest FY) | — | $-26.48M |
| Operating margin | — | -5219.12% |
| Net margin | — | -4646.14% |
| 52-week high | $10.28 | $46.95 |
| 52-week low | $9.90 | $16.05 |
| Distance from 52-week high | 0.00% | -61.00% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +211.31% |
| Average volume | 14.46K | 92.05K |
| Shares outstanding | 11.94M | 9.30M |
| Employees | — | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
EMIS vs YARW FAQ
Which is bigger, Emmis Acquisition or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $170.36M compared with $162.18M for Emmis Acquisition (EMIS).
Which stock has performed better over the past year, EMIS or YARW?
EMIS returned +3.32% over the past 12 months, compared with -3.12% for YARW (price return, excluding dividends). Past performance does not predict future results.
Are Emmis Acquisition and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.